Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMACare: lutetium [177Lu] vipivotide tetraxetan alone or with androgen receptor pathway inhibitors in PSMA-positive castration-resistant prostate cancer
2022-503040-41-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan, enzalutamide, apalutamide and darolutamide in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: PSA response rate. Planned start Dec 2023; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetanenzalutamideapalutamidedarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-503040-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503040-41-00.